Clinical significance of simultaneous determination of serum soluble transferrin receptor, soluble Fas, soluble Fas ligand, hepatocyte growth factor and interleukin 18 levels in a patient with hemophagocytic syndrome

Acta Haematol. 2000;103(3):165-7. doi: 10.1159/000041041.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Epstein-Barr Virus Infections / complications
  • Fas Ligand Protein
  • Female
  • Hepatocyte Growth Factor / blood*
  • Histiocytosis, Non-Langerhans-Cell / blood*
  • Histiocytosis, Non-Langerhans-Cell / etiology
  • Histiocytosis, Non-Langerhans-Cell / surgery
  • Humans
  • Interleukin-18 / blood*
  • Lymphoma, Non-Hodgkin / diagnosis
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / surgery
  • Membrane Glycoproteins / blood*
  • Neoplasm Proteins / blood*
  • Prednisone / administration & dosage
  • Receptors, Transferrin / blood*
  • Splenectomy
  • Tumor Virus Infections / complications
  • Vincristine / administration & dosage
  • fas Receptor / blood*

Substances

  • FASLG protein, human
  • Fas Ligand Protein
  • Interleukin-18
  • Membrane Glycoproteins
  • Neoplasm Proteins
  • Receptors, Transferrin
  • fas Receptor
  • Vincristine
  • Hepatocyte Growth Factor
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol